Skip to content
Home/Companies/Biotech/Mnemo Therapeutics

Mnemo Therapeutics

Biotech·France·Active·5yr hold
Entry
2021
Hold
5yr
Status
Active

Who owns Mnemo Therapeutics?

Mnemo Therapeutics is a French Biotech company, currently owned by Sofinnova Partners since 2021.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital X · 2021 · Life Sciences VC

Key facts

HQFrance
SectorBiotech

More from Sofinnova Capital X

Other portfolio companies in the same fund.

DISCO Pharmaceuticals
Active
BiotechGermany· 2023
Freya Biosciences
Freya Biosciences
Active
BiotechDenmark· 2023
May Health
May Health
Active
MedTechFrance· 2023
Nuage Therapeutics
Nuage Therapeutics
Active
BiotechSpain· 2023
T-Therapeutics
T-Therapeutics
Active
BiotechUK· 2023
Catamaran Bio
Catamaran Bio
Active
BiotechUS· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Mnemo Therapeutics?

Mnemo Therapeutics is currently owned by Sofinnova Partners, through Sofinnova Capital X, since 2021.

When did Sofinnova Partners acquire Mnemo Therapeutics?

Sofinnova Partners acquired Mnemo Therapeutics in 2021.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue